GSK (HAM:GS70) Short Ratio

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:GS70 GSK PLC HAM:GS70
82 GF Score
Price €46.00
GF Value €38.97
! 1 Warning Sign
View Full Analysis

What is GSK Short Ratio?

Short Ratio is a metric signaling prevailing investors' sentiment with a company. It represents the number of days it takes short sellers on average to repurchase all the shares short.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

HAM:GS70
82GF Score
GSK PLC HAM:GS70
Short Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is GSK (HAM:GS70) Overvalued in 2026?

Based on GuruFocus' analysis, GSK stock appears to be overvalued. The current stock price of €46.00 is trading 18% above its estimated GF Value™ of €38.97.

Key valuation signals for HAM:GS70:

  • Short Ratio:
  • GF Value™: €38.97 vs. price of €46.00 (18% above fair value)
  • GF Score™: 82/100 with 1 warning sign

No single metric tells the full story. See the HAM:GS70 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GSK Business Description

Address 79 New Oxford Street, London, GBR, WC1A 1DG
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
82GF Score

Get the complete analysis for HAM:GS70

Short Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€46.00
Price
€38.97
GF Value